.png){kind=icon}
返回
F
Filippo Pietrantonio
Fondazione IRCCS Istituto Nazionale dei Tumori
61H指数
1.0K论文数
1.6W被引数
收录论文 293
发表时间
.png){kind=icon}
Reply letter to comments on: Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial回复信函：关于“年龄和性别对ramucirumab联合紫杉醇作为转换维持治疗与继续一线奥沙利铂为基础化疗的疗效和安全性的影响：ARMANI III期试验的亚组分析”的评论.png)
ESMO Open.png)
OAAI
ESMO OpenIF8.3
OAAI.png){kind=icon}
分享.png){kind=icon}
收藏Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials原发肿瘤侧别及负超选择对RAS野生型转移性结直肠癌患者抗EGFR为基础维持疗法的影响：两项随机临床试验的个体患者数据合并分析OAAI
OAAI分享收藏Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trialKRASG12C突变化疗难治性转移性结直肠癌患者接受Sotorasib联合帕尼单抗或标准治疗（CodeBreaK 300）：一项III期随机临床试验的结果OAAI
OAAI分享收藏
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studiesFOLFOXIRI和FOLFOX/FOLFIRI两种一线方案，无论是否联合贝伐珠单抗，其相对剂量强度均会影响转移性结直肠癌患者的预后：TRIBE和TRIBE2研究的合并分析
PREAI
分享收藏Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trialBMC CANCEROAAI
BMC CANCERIF3.4
OAAI分享收藏